Summary
Childhood hyperactivity is a common behavioural complaint. The therapeutic options for physicians caring for children with hyperactivity are considerable and varied; current recommendations call for a multidisciplinary approach, including when necessary the use of drug therapy. Central nervous system stimulants are the primary agents used in the therapy of hyperactivity. The majority of children with hyperactivity diagnosed using careful clinical criteria will demonstrate short term benefits in cognitive and behavioural terms, but long term efficacy remains controversial. There appears to be a subset of patients who do not demonstrate a beneficial response to stimulants, although there is controversy as to whether this may be dose dependent. The adverse effects of most concern are suppression of growth, the development of tics and the potential for abuse. Antidepressants and clonidine are useful agents for the therapy of patients resistant to stimulant therapy. Although the most frequent adverse events of antidepressant therapy are associated with the anticholinergic activity of these agents, the most common serious adverse events are associated with antidepressant overdose. Concern has been expressed because of case reports describing an association between antidepressant therapy for hyperactivity and sudden death.
A number of other therapies have been used for hyperactivity. Although these therapies may be effective in subsets of patients with hyperactivity, there is little research detailing how to identify patients who might be expected to respond to such treatment.
Similar content being viewed by others
References
Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN, et al. Clinical effects of methylphenidate and thioridazine in intellctually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry 30: 246–256, 1991
Aman MG, Turbott SH. Prediction of clinical response in children taking methylphenidate. Journal of Autism and Developmental Disorders 21: 211–228, 1991
American Psychiatric Association. Diagnostic and statistical manual, 3rd ed., American Psychiatric Association Press, Washington, D.C., 1987
Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, et al. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to d-amphetamine. Biological Psychiatry 25: 222–228, 1989
Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In Gilman et al. (Eds) The pharmacological basis of therapeutics, 7th ed., pp. 387–445, Macmillan Publishing Inc., New York, 1985
Barkley RA. A critique of current diagnostic criteria for attention deficit hyperactivity disorder: clinical and research implications. Journal of Behavioural and Developmental Pediatrics 11: 343–352, 1990
Barkley RA, McMurray MB, Edelbrook CS, Robbyns K. Side effects of methylphenidate (Ritalin) in children with ADHD: a systemic, placebo-controlled evaluation. Pediatrics 86: 184–192, 1990
Bartlett MF, Egger HP. Disposition and metabolism of methyl-phendilate in dog and man. Federation Proceedings 31: 537, 1972
Beaumont G. Drug interactions with clomipramine (Anafranil). Journal of International Medical Research 1: 480, 1973
Biedermann J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo-controlled study of desipramine in the treatment of ADD: I, efficacy. Journal of the American Academy of Child and Adolescent Psychiatry 28: 777–784, 1989
Biedermann J, Gonzalez E, Bronstein B, De Monaco H, Wright V. Desipramine and cutaneous reactions in pediatric outpatients. Journal of Clinical Psychiatry 49: 178–183, 1988
Blackwell B, Paterson GR, Kizma RJ. The effect of five tricyclic antidepressants on salivary flow and mood in healthy volunteers. Communications in Psychopharmacology 4: 255–261, 1980
Bowen J, Fenton T, Rappoport L. Stimulant medication and attention deficit-hyperactivity disorder: the child’s perspective. American Journal of Diseases of Children 145: 291–295, 1991
Bradley C. The behaviour of children receiving benzedrine. American Journal of Psychiatry 94: 577–585, 1937
Brown HGE, McMichen HN, Briggs DS. Tachyarrhythmia in severe imipramine overdose controlled by practolol. Archives of Disease in Childhood 47: 104, 1972
Brown RP, Ingber PS, Tross S. Pemoline and lithium in a patient with attention deficit disorder. Journal of Clinical Psychiatry 44: 146–148, 1983
Brown RT, Sexson SB. Effects of methylphendilate on cardiovascular responses in attention deficit hyperactivity disordered adolescents. Journal of Adolescent Health Care 10: 179–183, 1989
Cantwell DP. Genetics of hyperactivity. Journal of Child Psychiatry and Psychology 16: 261–264, 1975
Charles L, Schain RJ, Guthrie D. Long term use and discontinuation of methylphendilate on hyperactive children’s ability to sustain attention. Pediatrics 64: 412–418, 1979
Cox J. WH. An indication for use of imipramine in attention deficit disorder. American Journal of Psychiatry 139: 1059–1060, 1982
Croche AF, Lipman RS, Overall JE, Hung W. The effects of stimulant medication on the growth of hyperactive children. Pediatrics 63: 847–850, 1979
Cunningham CE, Siegel LS, Offord DR. A dose-response analysis of the effects of methylphendilate on the peer interactions and simulated classroom performance of ADD children with and without conduct disorders. Journal of Child Psychology and Psychiatry 32: 439–452, 1991
Davy T, Rodgers CL. Stimulant medication and short attention span: a clinical approach. Developmental and Behavioural Pediatrics 10: 313–318, 1989
Donnelly M, Rapoport JL, Potter WZ, Oliver J, Keysor CS, et al. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity-clinical and biochemical findings. Archives of General Psychiatry 46: 205–212, 1989
Dulcan MK. Attention deficit disorder: evaluation and treatment. Pediatric Annals 14: 383–400, 1985
Eisenberg J, Asnis GM, van Praag HM, Vela RM. Effect of tyrosine on attentio. deficit disorder with hyperactivity. Journal of Clinical Psychiatry 49: 193–195, 1988
Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatry Research 36: 141–155, 1991
Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette’s syndrome: effects of stimulant drugs. Neurology 35: 1346–1348, 1985
Faraj BA, Israili ZH, Perel JM, Jenkins ML, Holtzman SG, et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. Journal of Pharmacology and Experimental Therapeutics 191: 535–547, 1974
Fulton AI, Yates WR. Family abuse of methylphenidate. American Family Practitioner 38: 143–145, 1988
Garfinkel BD, Wender PH, Sloman L, O’Neill I. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. Journal of the American Academy of Child Psychiatry 22: 343–348, 1983
Gittelman KR, Abikoff H. The role of psychostimulants and psychosocial treatmetns in hyperkinesis. In Sagvolden & Archer (Eds), Attention deficit disorder: clinical and basic research, pp. 167–180, Lawrence Erlbaum, Hillsdale, 1989
Golden GS. Gilles de la Tourette’s syndrome following methylphenidate administration. Developmental Medicine and Child Neurology 16: 76–78, 1974
Golden GS. The relationship between stimulant medication and tics. Pediatric Annals 17: 405–407, 1988
Grace ND, Berk D, Curtis G. Prolonged jaundice due to prolonged imipramine with recovery. Gastroenterology 58: 282, 1970
Gualtieri CT. The functional neuroanatomy of psychiatric treatments. Psychiatric Clinics of North America 14: 113–124, 1991
Gualtieri CT, Hicks RE, Patrick K, Schroeder SR, Breese GR, et al. Clinical correlates of methylphenidate blood levels. Therapeutic Drug Monitoring 6: 379–392, 1984
Gualtieri CT, Keenan PA, Chandler M. Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology 11: 155–159, 1991
Haggerty JJ, Jackson R. Mania following change from trazodone to imipramine. Journal of Clinical Psychiatry 5: 342–343, 1985
Haglund RM, Howerton LL. Ritalin: consequences of abuse in a clinical population. International Journal of Addiction 17: 349–356, 1982
Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 30: 241–245, 1991
Hicks RE, Mayo JP, Clayton CJ. Differential psychopharmacology of methylphendilate and the neuropsychology of childhood hyperactivity. International Journal of Neuroscience 45: 6–32, 1989
Hnatho SZ, Stirrat JH, Verchomin J, Ramsey CG. Agranulocytosis associated with imipramine. Canadian Medical Association Journal 92: 33–35, 1965
Hubbard JW, Srinivas NR, Quinn D, Midho KK. Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. Journal of Pharmaceutical Sciences 78: 944–947, 1989
Huessy HR, Wright AL. Graded imipramine regimen favored in hyperkinetic children. Journal of the American Medical Association 208: 1613–1614, 1969
Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG. Pharmacokinetics of methylphenidate in hyperkinetic children. British Journal of Clinical Pharmacology 8: 571–576, 1979
Hunt RD, Capper L, O’Connell P. Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psycho-pharmacology 1: 87–102, 1990
Kalachnik JE, Sprague RL, Sleator EK, Cohen NM, Ullmann RK. Effect of methylphenidate hydrochloride on stature of hyperactive children. Developmental Medicine and Child Neurology 24: 586–595, 1982
Kaplan BJ, McNicol J, Conte RA, Moghadam HK. Dietary replacement in preschool-aged hyperactive boys. Pediatrics 83: 7–17, 1989
Kimball JG. Hypothesis for prediction of stimulant drug effectiveness utilising sensory integrative diagnostic methods. Journal of the American Osteopathic Association 88: 757–761, 1988
Klein JJ, Segal RL, Warner RRP. Galactorrhoea due to imipramine: report of a case. New England Journal of Medicine 271: 510–512, 1964
Klein RG, Landa B, Mattes JA, Klein DF. Methylphenidate and growth in hyperactive children: a controlled withdrawal study. Archives of General Psychiatry 45: 1127–1130, 1988a
Klein RG, Mannuzza S. Hyperactive boys almost grown up III-methylphenidate effects on ultimate height. Archives of General Psychiatry 45: 1131–1134, 1988b
Kronfol Z, Greden JF, Zis A. Imipramine-induced tremor: effects of a beta-adrenergic blocking agent. Journal of Clinical Psychiatry 44: 225–226, 1983
Linnoila M, Gualtieri CT, Jobson K, Staye J. Characteristics of the therapeutic response to imipramine in hyperactive children. American Journal of Psychiatry 141: 906–908, 1979
Liskin B, Walsh BT, Roose SP, Jackson W. Imipramine-induced inappropriate ADH secretion. Journal of Clinical Psychophar-macology 4: 146–147, 1984
Lou HC, Henriksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Archives of Neurology 41: 825–829, 1984
Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette’s syndrome. Journal of the American Medical Association 247: 1168–1169, 1982
Lund-Larsen PG, Silvertssen E. Imipramine cardiotoxicity. Nordic Medicine 80: 986, 1968
Mandoki MW, Sumner GA, Matthews-Ferrari K. Subcategories of attention deficit hyperactivity disorder. Southern Medical Journal 84: 751–754, 1991
Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose and management of complications. American Heart Journal 103: 401–414, 1982
Martin CA, Vore M, Potts BD, Kryscio RJ, Norton JC, et al. Methylphenidate plasma concentrations in chronically and acutely treated latency-age children. Pharmacology 39: 46–49, 1989
McCormick MC, Gortmaker SL, Sobol AM. Very low birth weight children: behaviour problems and school difficulty in a national sample. Journal of Pediatrics 117: 687–693, 1990
Orsulak PJ, Waller D. Antidepressant drugs: additional clinical uses. Journal of Family Practice 28: 209–216, 1989
Ouellette EM. Legal issues in the treatment of children with attention deficit hyperactivity disorder. Journal of Child Neurology 6: S68–S75, 1991
Pendergast W, Taylor E, Rapoport JL, Bartko J, Donnelly M, Zametkin A, et al. The diagnosis of childhood hyperactivity. A US-UK cross-national study of DSM-III and ICD-9. Journal of Child Psychology and Psychiatry 29: 289–300, 1988
Pettinger WA, Soyangco FG, Oates JA. Inhibition of monoamine oxidase in man by furazolidine. Clinical Pharmacology and Therapeutics 9: 442–447, 1968
Phillips S. The use of stimulant medication with children. Developmental and Behavioural Pediatrics 10: 319–320, 1989
Raisfeld IH. Cardiovascular complications of antidepressant therapy. American Heart Journal 83: 129–133, 1972
Rapoport J, Mekkleson EJ. Childhood enuresis II: psychopathology tricyclic concentration in plasma and antienuretic effects. Archives of General Psychiatry 37: 1146–1152, 1980
Rapoport JL, Ferguson HB. Biological validation of the hyperkinetic syndrome. Developmental Medicine and Child Neurology 23: 667–682, 1981
Reeves JC, Werry JS, Elkin GS, Zametkin A. Attention deficit, conduct, oppositional, and anxiety disorders in children: II. Clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry 26: 144–155, 1987
Riddle MA, Nelson JC, Kleinman CS, Rasmusson A, Leckman JF, et al. Sudden death in children receiving Norpramin™: a review of three reported cases and commentary. Journal of the American Academy of Child and Adolescent Psychiatry 30: 104–108, 1991
Rostain AL. Attention deficit disorders in children. Pediatric Clinics of North America 38: 607–635, 1991
Rutter M. Diagnostic validity in child psychiatry. Advances in Biological Psychiatry 2: 2–22, 1978
Safer D, Allen RP, Barr E. Depression of growth in hyperactive children on stimulant drugs. New England Journal of Medicine 287: 217–220, 1972
Safer D, Allen RP. Absence of tolerance to the behavioural effects of methylphendilate in hyperactive and inattentive children. Journal of Pediatrics 115: 1003–1008, 1989
Safer D, Krager JM. A survey of medication treatment for hyperactive/inattentive students. Journal of the American Medical Association 260: 2256–2258, 1988
Safer D, Krager JM. Hyperactivity and inattentiveness: school assessment of stimulant treatment. Clinical Pediatrics 28: 216–221, 1989
Salem RM, Fischer RG, Horton M. Lack of cross-allergenicity between tricyclic antidepessants. Southern Medical Journal 75: 1020–1021, 1982
Sallee FR, Stiller RL, Perel JM. Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry 31: 244–251, 1992
Sallee FR, Stiller RL, Perel JM, Bates TR. Oral pemoline kinetics in hyperactive children. Clinical Pharmacology and Therapeutics 37: 606–609, 1985
Satterfield JH, Cantwell DP, Schell A, Bluschke T. Growth of hyperactive children treated with methylphenidate. Archives of General Psychiatry 36: 212–217, 1979
Satterfield JH, Hoppe CM, Schell AM. A prospective study of delinquency in 110 adolescent boys with attention deficit disorder and 88 normal adolescent boys. American Journal of Psychiatry 139: 795–798, 1982
Schachar R. Childhood hyperactivity. Journal of Child Psychology and Psychiatry 32: 155–191, 1991
Shaefer MS, Edmunds AL, Markin RS, Wood RW, Pillen TJ, et al. Hepatic failure associated with imipramine therapy. Pharmacotherapy 10: 66–69, 1990
Shapiro, SK, Garfinkel BD. The occurrence of behaviour disorders in children: the interdependence of attention deficit disorder and conduct disorder. Journal of the American Academy of Child Psychiatry 25: 809–819, 1986
Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behaviour. Science 198: 1274–1276, 1977
Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha KK. Extensive and enantioselective presystemic metabolism of dlthreo-methylphendilate in humans. Progress in Neurophychopharmacology and Biological Psychiatry 15: 213–220, 1991
Stahl ML, Orr WC, Griffiths WJ. Nocturnal levels of growth hormone in hyperactive children of small stature. Journal of Child Psychiatry 40: 225–227, 1979
Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America 36: 1183–1197, 1989
Szatmari P, Boyle M, Offord DR. ADDH and conduct disorder: degree of diagnostic overlap and differences among correlates. Journal of the American Academy of Child and Adolescent Psychiatry 28: 865–872, 1989
Tannock R, Schachter RJ, Carr RP, Login GD, et al. Dose-response effects of methylphendilate on academic performance and overt behaviour in hyperactive children. Pediatrics 84: 648–657, 1989
Trommer BL, Hoeppner JB, Zecker SG. The go-no go test in attention deficit disorder is sensitive to methylphendilate. Journal of Child Neurology 6: S128–S131, 1991
Vitiello S, Stoff D, Atkins M, Mahoney A. Soft neurological signs and impulsivity in children. Journal of Developmental and Behavioural Pediatrics 11: 112–115, 1990
Weinberg WA, Emslie GJ. Attention deficit hyperactivity disorder: the differential diagnosis. Journal of Child Neurology 6: S21–S34, 1991
Weiner N. Norepinephrine, epinephrine and the sympathomimetic amines. In Gilman et al. (Eds) The pharmacological basis of therapeutics, 7th ed., pp. 145–180, Macmillan Publishing Inc., New York, 1985
Werry JS, Aman MG, Diamond E. Imipramine and methylphendilate in hyperactive children. Journal of Child Psychology and Psychiatry 21: 27–35, 1980
Winsberg BG, Bialer I, Kupitcz S, Tobias J. Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. American Journal of Psychiatry 128: 1425–1431, 1972
Winsberg BG, Kupietz SS, Sverd J, Hungund BL, Young NL. Methylphenidate oral plasma concentrations and behavioural response in children. Psychopharmacology 76: 329–332, 1982
Zametkin AJ, Borcherding BG. The neuropharmacology of attention-deficit hyperactivity disorder. Annual Review of Medicine 40: 447–451, 1989
Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. New England Journal of Medicine 323: 1361–1366, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, A.M., Rieder, M.J. Risks and Benefits of Drugs Used in the Management of the Hyperactive Child. Drug-Safety 9, 38–50 (1993). https://doi.org/10.2165/00002018-199309010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199309010-00004